



# Re-evaluation of the occupational exposure limit for ZnO is warranted. Comments on 'Systemic inflammatory effects of zinc oxide particles: is a re-evaluation of exposure limits needed?' by Christian Monsé et al.

Ulla Vogel<sup>1</sup> · Anne T. Saber<sup>1</sup> · Nicklas R. Jacobsen<sup>1</sup> · Pernille H. Danielsen<sup>1</sup> · Karin S. Hougaard<sup>1</sup> · Niels Hadrup<sup>1</sup>

Received: 19 September 2023 / Accepted: 7 November 2023 / Published online: 1 December 2023  
© The Author(s) 2023

Christian Monsé and co-workers recently published a Short Communication in Archives of Toxicology (Monse et al. 2023) commenting on the suggested health-based occupational exposure limit for zinc oxide made by the National Research Centre for the Working Environment (NFA) in Denmark (Hadrup et al. 2021b).

In 2018, Christian Monsé and co-workers made a controlled human exposure study (Monse et al. 2018), which reproduced the dose-dependent ZnO-induced acute phase response in human volunteers that we have previously observed in mice (Hadrup et al. 2019; Jacobsen et al. 2015; Saber et al. 2022), and enabled NFA to derive a health-based occupational exposure limit based on human data. Our suggestion was 0.05 mg/m<sup>3</sup> ZnO. In the recent short communication, Monsé and et al. argues that a higher OEL for ZnO could be justified. We would like to address some of their arguments.

We agree with Monsé et al. that the No Observed Effect Concentration (NOEC) for systemic acute phase response is 0.5 mg/m<sup>3</sup> ZnO for 4 h. We furthermore consider it a No Observed Adverse Effect Concentration (NOAEC), because we consider the induced effects as adverse. As also mentioned by Monsé et al., Brand et al. showed, in their controlled human exposure studies, that the biologically relevant dose is the total daily dose calculated as time x concentration (Brand et al. 2019). We argue that the same dose–response relationship would be expected in the range of the NOAEC, and therefore, the derived NOAEC for an 8-h working day should be 0.25 mg/m<sup>3</sup> (ECHA 2012).

ZnO exposure induces dose-dependent acute phase response in humans and mice (Hadrup et al. 2019; Jacobsen et al. 2015; Saber et al. 2022; Monse et al. 2023). The

acute phase response is the systemic response to acute and chronic inflammatory states caused by, e.g. bacterial infection, trauma and infarction (Gabay and Kushner 1999). The acute phase protein Serum Amyloid A (SAA) is causally related to atherosclerosis and cardiovascular disease (Hadrup et al. 2020; Thompson et al. 2018). Overexpression of SAA promotes atherosclerosis in mouse models (Christophersen et al. 2021; Thompson et al. 2018). Blood levels of SAA and C-reactive protein (CRP) are closely correlated in blood. In prospective, epidemiological studies, even very moderate increases in SAA and CRP concentrations in blood are associated with increased risk of cardiovascular (Pai et al. 2004; Ridker et al. 2000). Since cardiovascular diseases such as atherosclerosis, apoplexia and ischemic heart disease are extremely prevalent, even small increases in the risk of cardiovascular disease are relevant, also in the working environment.

Monsé et al. argue that the ZnO-induced acute phase response is a substance-specific effect. We disagree. We acknowledge that a particle-dependent acute phase response differs for soluble and insoluble materials, e.g. as shown for metal oxides (Gutierrez et al. 2023). Soluble metal oxides, such as CuO or ZnO, that undergo dissolution in lysosomes induce a strong acute phase response in humans and mice (Brand et al. 2019; Gutierrez et al. 2023; Hadrup et al. 2021a). The acute phase response of soluble particles is transient and independent of particle size (Monse et al. 2021). On the other hand, in mice, insoluble particles will induce long-lasting acute phase response, which is predicted by the total surface area of the deposited particles (Danielsen et al. 2019; Gutierrez et al. 2023; Hadrup et al. 2021a; Poulsen et al. 2017; Saber et al. 2014). There is also evidence in humans for particle-induced acute phase response by insoluble particles. In a controlled human study, 4 h of exposure to 38 µg /m<sup>3</sup> PM2.5 caused a 9% increase in SAA levels (Wyatt et al. 2020). In a study of air pollution and CRP levels in 30,000 Taiwanese, a 5 µg increase in PM2.5 levels

✉ Ulla Vogel  
ubv@nrcwe.dk

<sup>1</sup> National Research Centre for the Working Environment, Copenhagen, Denmark

was associated with 1.3% increased CRP levels (Zhang et al. 2017).

Monsé et al. argue that ‘the transferal from young and healthy subjects to the general working population should not represent a relevant problem’ and argues against the use of assessment factor to account for inter-individual variation. We would like to point out that lifestyle factors such as BMI, smoking and exercise modify the acute phase response (Jylhava et al. 2009) and that low-grade inflammation, which includes slightly elevated acute phase response, is a risk factor for other major diseases such as type 2 diabetes. We have little knowledge on possible combination effects. We also note that a factor of 5 is the default intra-species assessment factor for workers by ECHA (ECHA 2012, 2019).

In conclusion, Monsé and co-workers have performed important controlled studies on ZnO that replicated the ZnO-induced acute phase response in humans that we have observed in mice. Compared to the current Danish occupational exposure limit for ZnO at 5 mg/m<sup>3</sup>, an exposure limit for ZnO of 0.1 mg/m<sup>3</sup> as suggested by the MAK commission (Monse et al. 2023) and a health-based occupational exposure limit at 0.05 as suggested by us (Hadrup et al. 2021b) may be regarded as being very similar.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Brand P, Beilmann V, Thomas K et al (2019) The effects of exposure time on systemic inflammation in subjects with exposure to zinc- and copper-containing brazing fumes. *J Occup Environ Med* 61(10):806–811. <https://doi.org/10.1097/JOM.0000000000001676>
- Christophersen DV, Moller P, Thomsen MB et al (2021) Accelerated atherosclerosis caused by serum amyloid A response in lungs of ApoE(-/-) mice. *FASEB J* 35(3):e21307. <https://doi.org/10.1096/fj.202002017R>
- Danielsen PH, Knudsen KB, Strancar J et al (2019) Effects of physicochemical properties of TiO<sub>2</sub> nanomaterials for pulmonary inflammation, acute phase response and alveolar proteinosis in intratracheally exposed mice. *Toxicol Appl Pharmacol*. <https://doi.org/10.1016/j.taap.2019.114830>
- ECHA (2012) Guidance on information requirements and chemical safety assessment Chapter R.8: characterisation of dose [concentration]-response for human health. ECHA
- ECHA (2019) Guidance on information requirements and chemical safety assessment Appendix to Chapter R.8: Guidance for preparing a scientific report for health-based exposure limits at the workplace. ECHA
- Gabay C, Kushner I (1999) Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 340(6):448–454
- Gutierrez CT, Loizides C, Hafez I et al (2023) Acute phase response following pulmonary exposure to soluble and insoluble metal oxide nanomaterials in mice. *Part Fibre Toxicol* 20(1):4. <https://doi.org/10.1186/s12989-023-00514-0>
- Hadrup N, Rahmani F, Jacobsen NR et al (2019) Acute phase response and inflammation following pulmonary exposure to low doses of zinc oxide nanoparticles in mice. *Nanotoxicology* 13(9):1275–1292. <https://doi.org/10.1080/17435390.2019.1654004>
- Hadrup N, Zhernovkov V, Jacobsen NR et al (2020) Acute phase response as a biological mechanism-of-action of (nano)particle-induced cardiovascular disease. *Small* 16(21):e1907476. <https://doi.org/10.1002/sml.201907476>
- Hadrup N, Aimonen K, Ilves M et al (2021a) Pulmonary toxicity of synthetic amorphous silica - effects of porosity and copper oxide doping. *Nanotoxicology* 15(1):96–113. <https://doi.org/10.1080/17435390.2020.1842932>
- Hadrup N, Saber AT, Jacobsen NR et al (2021b) Zinc oxide: Scientific basis for setting a health-based occupational exposure limit. National Research Centre for the Working Environment, Copenhagen
- Jacobsen NR, Stoeger T, van den Brule S et al (2015) Acute and subacute pulmonary toxicity and mortality in mice after intratracheal instillation of ZnO nanoparticles in three laboratories. *Food Chem Toxicol* 85:84–95. <https://doi.org/10.1016/j.fct.2015.08.008>
- Jylhava J, Haarala A, Eklund C et al (2009) Serum amyloid A is independently associated with metabolic risk factors but not with early atherosclerosis: the Cardiovascular Risk in Young Finns Study. *J Intern Med* 266(3):286–295. <https://doi.org/10.1111/j.1365-2796.2009.02120.x>
- Monse C, Hagemeyer O, Raulf M et al (2018) Concentration-dependent systemic response after inhalation of nano-sized zinc oxide particles in human volunteers. *Part Fibre Toxicol* 15(1):8
- Monse C, Raulf M, Jettkant B et al (2021) Health effects after inhalation of micro- and nano-sized zinc oxide particles in human volunteers. *Arch Toxicol* 95(1):53–65. <https://doi.org/10.1007/s00204-020-02923-y>
- Monse C, Merget R, Bunger J, Pallapies D, Bruning T (2023) Systemic inflammatory effects of zinc oxide particles: is a re-evaluation of exposure limits needed? *Arch Toxicol*. <https://doi.org/10.1007/s00204-023-03567-4>
- Pai JK, Pischon T, Ma J et al (2004) Inflammatory markers and the risk of coronary heart disease in men and women. *N Engl J Med* 351(25):2599–2610
- Poulsen SS, Knudsen KB, Jackson P et al (2017) Multi-walled carbon nanotube-physicochemical properties predict the systemic acute phase response following pulmonary exposure in mice. *PLoS ONE* 12(4):e0174167
- Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 342(12):836–843
- Saber AT, Jacobsen NR, Jackson P et al (2014) Particle-induced pulmonary acute phase response may be the causal link between particle inhalation and cardiovascular disease. *Wires Nanomed Technol*. <https://doi.org/10.1002/wnan.1279>
- Saber AT, Hadrup N, Williams A et al (2022) Unchanged pulmonary toxicity of ZnO nanoparticles formulated in a liquid matrix for glass coating. *Nanotoxicology* 16(6–8):812–827. <https://doi.org/10.1080/17435390.2022.2152751>
- Thompson JC, Wilson PG, Shridas P et al (2018) Serum amyloid A3 is pro-atherogenic. *Atherosclerosis* 268:32–35

- Wyatt LH, Devlin RB, Rappold AG, Case MW, Diaz-Sanchez D (2020) Low levels of fine particulate matter increase vascular damage and reduce pulmonary function in young healthy adults. *Part Fibre Toxicol* 17(1):58. <https://doi.org/10.1186/s12989-020-00389-5>
- Zhang Z, Chang LY, Lau AKH et al (2017) Satellite-based estimates of long-term exposure to fine particulate matter are associated with C-reactive protein in 30 034 Taiwanese adults. *Int J Epidemiol* 46(4):1126–1136

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.